Rajender Reddy K, Modi MW, Pedder S (June 2002). 《Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C》. 《Advanced Drug Delivery Reviews》 54. 571–86쪽. doi:10.1016/s0169-409x(02)00028-5. PMID12052715.
Reddy U, Krzystolik M (2006). 《Antiangiogenic therapy with interferon alfa for neovascular age-related macular degeneration》. 《Cochrane Database of Systematic Reviews》 1. CD005138쪽. doi:10.1002/14651858.CD005138.pub2. PMID16437522.
World Health Organization (2019). 《World Health Organization model list of essential medicines: 21st list 2019》. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
Rajender Reddy K, Modi MW, Pedder S (June 2002). 《Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C》. 《Advanced Drug Delivery Reviews》 54. 571–86쪽. doi:10.1016/s0169-409x(02)00028-5. PMID12052715.
Reddy U, Krzystolik M (2006). 《Antiangiogenic therapy with interferon alfa for neovascular age-related macular degeneration》. 《Cochrane Database of Systematic Reviews》 1. CD005138쪽. doi:10.1002/14651858.CD005138.pub2. PMID16437522.